Workflow
Analysts Cite Amgen’s (AMGN) Strong Therapies Pipeline to Reaffirm Bullish Outlook
AmgenAmgen(US:AMGN) Yahoo Finance·2025-09-26 15:10

Group 1 - Amgen Inc. is recognized as one of the best value stocks in Goldman Sachs' portfolio, with a Buy rating maintained by Piper Sandler analyst David Amsellem and a price target of $342 [1] - The upcoming FORTITUDE-102 study results, which combine bemarituzumab with chemotherapy and Opdivo, are crucial for Amgen's market potential, as highlighted by William Blair analyst Matt Phipps [2] - Amgen's pipeline strength is exemplified by the recommendation for approval of Tezspire (tezepelumab) in the EU, developed in collaboration with AstraZeneca for treating chronic rhinosinusitis with nasal polyps, affecting approximately 320 million people globally [3] Group 2 - In the collaboration agreement for Tezspire, AstraZeneca leads development while Amgen is responsible for manufacturing, with costs and profits shared equally after AstraZeneca pays a mid-single-digit inventor royalty to Amgen [4] - Amgen focuses on discovering, developing, and manufacturing innovative therapies in oncology, cardiovascular disease, inflammation, and rare diseases [4]